Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same
申请人:GREEN CROSS CORPORATION
公开号:US10294207B2
公开(公告)日:2019-05-21
Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
本发明提供了吡唑衍生物作为 TNIK(Traf2-和 NCK-相互作用激酶)、IKKε(I-kappa-B 激酶 epsilon)和 TBK1(TANK 结合激酶 1)抑制剂;根据本发明的吡唑衍生物可有效抑制 TNIK、IKKε 和 TBK1,因此不仅可作为抗癌剂用于治疗各种癌症,包括结直肠癌、乳腺癌、中枢神经系统癌、结肠癌、非小细胞肺癌、肾癌、前列腺癌、卵巢癌、子宫癌、胃癌、乳腺癌、结肠癌、非小细胞肺癌、肾癌、前列腺癌、卵巢癌、子宫癌、胃癌、结肠癌、非小细胞肺癌、子宫癌、胃癌、肝癌、皮肤癌、肺癌、脑癌、膀胱癌、食道癌、胰腺癌、甲状腺癌、头颈部癌、鳞状细胞癌、骨肉瘤、B 细胞或 T 细胞淋巴瘤、急性或慢性白血病和多发性骨髓瘤,还可作为慢性炎症的治疗剂。